2 news items
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
IMVT
29 May 24
on Immunovant's business operations and supply chain, including its clinical development plans and timelines; Immunovant's business is heavily
Immunovant Awarded U.S. Patent for IMVT-1402
IMVT
12 Mar 24
, geopolitical tensions, and adverse macroeconomic conditions on Immunovant's business operations and supply chain, including its clinical development
- Prev
- 1
- Next